Summit: A Cautious Bet Backed By Anti-VEGF & Insider Buying (NASDAQ:SMMT)

Core Viewpoint - Summit Therapeutics (SMMT) is rated as a "cautious buy" due to the potential of its anti-PD-1 and anti-VEGF combination therapy, indicating a promising investment opportunity [1] Market Potential - If Summit Therapeutics captures just 4% of the market share by 2033, it could imply a potential annualized compound annual growth rate (CAGR) of 15% [1]